biosimilar portfolio
Scope
Date
~
-
Bio & Pharma
Celltrion to supply Remsima, Herzuma to Peru
South Korea's Celltrion Inc. announced on Thursday that it secured a contract to supply its biosimilars for autoimmune disease treatment and antican...
May 02, 2024 (Gmt+09:00)
-
Bio & Pharma
Samsung Bioepis gets OK to sell Stelara biosimilar in Europe
South Korea's Samsung Bioepis has received approval from the European Commission to sell Pyzchiva, a biosimilar of the autoimmune disease Stelara.&n...
Apr 23, 2024 (Gmt+09:00)
-
Corporate strategy
SK Innovation to adjust business portfolios for long-term growth
SK Innovation Co., South Korea’s top energy company, is slated to adjust its business portfolios for long-term growth while not planning to sl...
Apr 17, 2024 (Gmt+09:00)
-
Mergers & Acquisitions
Korea's M&A market poised to bounce back after bleak Q1
South Korea’s mergers and acquisitions market is poised to bounce back after a bleak first quarter, with 22.3 trillion won ($16 billion) worth...
Apr 11, 2024 (Gmt+09:00)
-
Economy
S.Korea’s current account surplus near 3-year high on chips
South Korea’s current account surplus touched a near three-year high in February as goods exports continued to grow on strong overseas sales o...
Apr 05, 2024 (Gmt+09:00)
-
Bio & Pharma
Samsung begins new drug development for rare diseases
Samsung Bioepis Co., a biosimilar development unit of South Korea’s top conglomerate Samsung Group, has begun its new drug development busines...
Mar 24, 2024 (Gmt+09:00)
-
Energy
Hanwha Solutions expands cable insulation materials units
South Korea's Hanwha Solutions Corp. is accelerating its entry into the global market with proprietary technology in high-voltage cable materials.Ha...
Mar 21, 2024 (Gmt+09:00)
-
Robotics
KT, Novatek to collaborate on logistics robot platform
South Korea's KT Corp. announced on Wednesday that it signed a memorandum of understanding (MOU) with the domestic company Novatek which specializes...
Mar 13, 2024 (Gmt+09:00)
-
Bio & Pharma
Samsung Bioepis to supply Hadlima to US government
South Korea’s Samsung Bioepis and the US-based Organon, the local partner company of Samsung group's biopharmaceutical research and developmen...
Feb 21, 2024 (Gmt+09:00)
-
Bio & Pharma
Aprogen gets OK Phase 3 trials in India for Herceptin biosimilar
South Korea’s biopharmaceutical company Aprogen Inc. announced on Monday that its Phase 3 clinical trial for a biosimilar of Herceptin (trastu...
Feb 05, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion to export three anticancer drugs to Europe
South Korea’s Celltrion Inc. announced on Thursday that it has secured supply contracts for three anticancer biosimilars in European countries...
Jan 18, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion Holdings eyes Nasdaq IPO by early 2025: chairman
South Korean biosimilar giant Celltrion Group is planning to debut on the Nasdaq market by early 2025, founder and Chairman Seo Jung-jin said at the...
Jan 16, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion to expand Yuflyma supply network in Europe
South Korea’s Celltrion Inc. announced on Friday that it will supply its biosimilar Yuflyma (active ingredient: adalimumab) for the treatment ...
Jan 12, 2024 (Gmt+09:00)
-
Korean innovators at CES 2024
Samsung, Harman move in lockstep to advance in-vehicle technology
LAS VEGAS – South Korea’s tech giant Samsung Electronics Co. and its wholly owned US subsidiary Harman International Industries Inc. hav...
Jan 10, 2024 (Gmt+09:00)
-
Bio & Pharma
Samsung eyes biotech investments via Flagship Pioneering
Samsung C&T Corp., Samsung Biologics Co. and Samsung Bioepis Co. will ramp up investments in US biotechnology startups in collaboration with Fla...
Jan 09, 2024 (Gmt+09:00)
-
Mergers & Acquisitions
Celltrion to sell portfolio of Takeda drugs to CBC Group
South Korea’s Celltrion Inc. will divest of a portfolio of Takeda Pharmaceutical's prescription medicines sold in Asia to CBC Group, a Singapo...
Jan 01, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion applies for approval of Xolair biosimilar in Canada
South Korean biopharmaceutical company Celltrion Inc. announced on Wednesday that it has applied for CT-P39, a biosimilar of the treatment of asth...
Dec 27, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion’s Vegzelma listed on US PBM preferred drug list
South Korea's Celltrion Healthcare Co. announced on Tuesday that its anti-cancer biosimilar Vegzelma (active ingredient: bevacizumab) was listed as ...
Dec 12, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion Healthcare's Herzuma selected as funded brand in NZ
Celltrion Healthcare Co. announced on Thursday that its biosimilar anticancer drug Herzuma (active ingredient trastuzumab) for breast and gastr...
Dec 07, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion applies for approval in Europe for eye treatment biosimilar
South Korean biopharmaceutical company Celltrion Inc. announced on Friday that it applied for approval from the European Medicines Agency (EMA) for ...
Nov 24, 2023 (Gmt+09:00)
-
Artificial intelligence
LG, Qraft Technologies' AI-powered ETF trades on NYSE
South Korea’s LG Group and Seoul-based Qraft Technologies Inc. have jointly launched an exchange-traded fund (ETF) that selects holdings relat...
Nov 08, 2023 (Gmt+09:00)
-
Earnings
Celltrion enjoys record earnings on healthy biosimilar biz
South Korean pharmaceutical giant Celltrion Inc. logged record quarterly earnings on the strong performance of its key biosimilar products while exp...
Nov 07, 2023 (Gmt+09:00)
-
Earnings
Hyundai Motor Group units’ profits double as Chung enters 4th year
South Korea’s Hyundai Motor Group saw the combined operating profit of its 11 affiliates more than double in the third quarter as Chairman Chu...
Nov 02, 2023 (Gmt+09:00)
-
Bio & Pharma
Samsung Bioepis gets FDA OK for its interchangeable biosimilar
Byooviz, a biosimilar of the macular degeneration treatment Lucentis and made by South Korea’s Samsung Bioepis, has received official design...
Oct 25, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion’s approved merger removes hurdle to three-way combination
South Korea’s biosimilar drugmaker Celltrion group on Monday moved one step closer to the planned combination of its three major affiliates wi...
Oct 23, 2023 (Gmt+09:00)
-
Bio & Pharma
Samsung Bioepis releases Soliris biosimilar in Europe
Samsung Bioepis Co., a biopharmaceutical research and development unit under South Korea's Samsung Group, is rolling out its latest product Epysqli,...
Oct 19, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion Healthcare to supply Yuflyma to US pharmacy chain
South Korea's Celltrion Healthcare Co. has inked a deal with the US specialty pharmacy chain CarePartners Pharmacy to supply its autoimmune disease ...
Oct 16, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion gets sales approval for Yuflyma in Japan
South Korea's biopharmaceutical company Celltrion Inc. announced on Tuesday that it has secured approval from the Japanese Ministry of Health, Labou...
Sep 26, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion signs largest-ever quarterly deal with global sales affiliate
Celltrion Inc., a South Korean biopharmaceutical giant, said Monday it will provide biosimilars worth 423.6 billion won ($323.6 million), its larges...
Sep 25, 2023 (Gmt+09:00)
-
Mergers & Acquisitions
SK Chemicals to sell pharmaceutical unit to Glenwood PE
SK Chemicals Co., a South Korean plastic materials producer, is in exclusive talks with Seoul-based Glenwood Private Equity to sell its pharmaceutic...
Sep 21, 2023 (Gmt+09:00)